John Zajecka to Dose-Response Relationship, Drug
This is a "connection" page, showing publications John Zajecka has written about Dose-Response Relationship, Drug.
Connection Strength
0.263
-
Evidence for the use of l-methylfolate combined with antidepressants in MDD. J Clin Psychiatry. 2011 Aug; 72(8):e25.
Score: 0.083
-
Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr; 30(2):135-44.
Score: 0.076
-
Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry. 1997; 58 Suppl 7:5-10.
Score: 0.030
-
A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015 Jul; 40(8):2025-37.
Score: 0.027
-
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec; 169(12):1267-74.
Score: 0.023
-
High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006 Jan; 67(1):15-22.
Score: 0.014
-
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001 Jan; 62(1):12-8.
Score: 0.010